(HealthDay): Weight loss drug is associated with the absence of atrial fibrillation (FFAF) in both obese and non-obese patients, according to a study published online June 30 in Journal of Cardiovascular Electrophysiology.
Graham Peigh, MD, of the Feinberg School of Medicine at Northwestern University in Chicago, and colleagues evaluated the impact of pre-FFAF weight changes after ablation in obese and non-obese patients. The analysis included 601 patients, of whom 234 were obese and 315 had paroxysmal AF.
The researchers found that 69.9% of patients achieved FFAF at 15 months. There was an independent association between the percentage of weight change during the year prior to ablation and FFAF for 15 months in all patients (adjusted probability ratio, 1.17). Similarly, the percentage of weight change during the year prior to ablation was independently associated with FFAF in all subgroups (paroxysmal versus persistent AF, presence of obesity, and history of previous ablation), except in non-obese patients with persistent AF.
Several authors revealed financial links with Medtronic.
Summary / Full text (subscription or payment may be required)
Copyright © 2021 HealthDay. All rights reserved.
Citation: Weight Loss of A-fib Freedom-Related Pre-Payment (2021, July 9) Retrieved July 9, 2021 at https://medicalxpress.com/news/2021-07-preablation-weight-loss -linked-freedom.html
This document is subject to copyright. Apart from any fair treatment for the purposes of private study or research, no part may be reproduced without written permission. Content is provided for informational purposes only.